Abstract
The proto-oncogene BCL6 encodes a BTB/POZ-zinc finger transcriptional repressor that is necessary for germinal-center formation and has been implicated in the pathogenesis of B-cell lymphomas. Here we show that the co-activator p300 binds and acetylates BCL6 in vivo and inhibits its function. Acetylation disrupts the ability of BCL6 to recruit histone deacetylases (HDACs), thereby hindering its capacity to repress transcription and to induce cell transformation. BCL6 is acetylated under physiologic conditions in normal germinal-center B cells and in germinal center–derived B-cell tumors. Treatment with specific inhibitors shows that levels of acetylation of BCL6 are controlled by both HDAC-dependent and SIR2-dependent pathways. Pharmacological inhibition of these pathways leads to the accumulation of the inactive acetylated BCL6 and to cell-cycle arrest and apoptosis in B-cell lymphoma cells. These results identify a new mechanism of regulation of the proto-oncogene BCL6 with potential for therapeutic exploitation. Furthermore, these findings provide a new mechanism by which acetylation can promote transcription not only by modifying histones and activating transcriptional activators, but also by inhibiting transcriptional repressors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ye, B.H. et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262, 747–750 (1993).
Ye, B.H. et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B-cell lymphoma. EMBO J. 14, 6209–6217 (1995).
Baron, B.W. et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc. Natl Acad. Sci. USA 90, 5262–5266 (1993).
Kerckaert, J.P. et al. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nature Genet. 5, 66–70 (1993).
Zollman, S., Godt, D., Prive, G.G., Couderc, J.L. & Laski, F.A. The BTB domain, found primarily in zinc finger proteins, defines an evolutionarily conserved family that includes several developmentally regulated genes in Drosophila. Proc. Natl Acad. Sci. USA 91, 10717–10721 (1994).
Chang, C.C., Ye, B.H., Chaganti, R.S. & Dalla-Favera, R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc. Natl Acad. Sci. USA 93, 6947–6952 (1996).
Seyfert, V.L., Allman, D., He, Y. & Staudt, L.M. Transcriptional repression by the proto-oncogene BCL-6. Oncogene 12, 2331–2342 (1996).
Dhordain, P. et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 26, 4645–4651 (1998).
Dhordain, P. et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc. Natl Acad. Sci. USA 94, 10762–10767 (1997).
Wong, C.W. & Privalsky, M.L. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARα, and BCL-6. J. Biol. Chem. 273, 27695–27702 (1998).
Cattoretti, G. et al. BCL-6 protein is expressed in germinal-center B cells. Blood 86, 45–53 (1995).
Onizuka, T. et al. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal-center B cells and their neoplastic counterparts. Blood 86, 28–37 (1995).
Rajewsky, K. Clonal selection and learning in the antibody system. Nature 381, 751–758 (1996).
Ye, B.H. et al. The BCL-6 proto-oncogene controls germinal-center formation and Th2-type inflammation. Nature Genet. 16, 161–170 (1997).
Dent, A.L., Shaffer, A.L., Yu, X., Allman, D. & Staudt, L.M. Control of inflammation, cytokine expression, and germinal-center formation by BCL-6. Science 276, 589–592 (1997).
Shaffer, A.L. et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell-cycle control. Immunity 13, 199–212 (2000).
Reljic, R., Wagner, S.D., Peakman, L.J. & Fearon, D.T. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J. Exp. Med. 192, 1841–1848 (2000).
Harris, M.B. et al. Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of iepsilon transcription and immunoglobulin E switching. Mol. Cell. Biol. 19, 7264–7275 (1999).
Niu, H., Ye, B.H. & Dalla-Favera, R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 12, 1953–1961 (1998).
Allman, D. et al. BCL-6 expression during B-cell activation. Blood 87, 5257–5268 (1996).
Shen, H.M., Peters, A., Baron, B., Zhu, X. & Storb, U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280, 1750–1752 (1998).
Migliazza, A. et al. Frequent somatic hypermutation of the 5′ noncoding region of the BCL6 gene in B-cell lymphoma. Proc. Natl Acad. Sci. USA 92, 12520–12524 (1995).
Pasqualucci, L. et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc. Natl Acad. Sci. USA 95, 11816–11821 (1998).
Artiga, M.J. et al. A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas. Am. J. Pathol. 160, 1371–1380 (2002).
Sterner, D.E. & Berger, S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64, 435–459 (2000).
Barlev, N.A. et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8, 1243–1254 (2001).
Gu, W. & Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595–606 (1997).
Roth, S.Y., Denu, J.M. & Allis, C.D. Histone acetyltransferases. Annu. Rev. Biochem. 70, 81–120 (2001).
Chan, H.M., Krstic-Demonacos, M., Smith, L., Demonacos, C. & La Thangue, N.B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nature Cell Biol. 3, 667–674 (2001).
Martinez-Balbas, M.A., Bauer, U.M., Nielsen, S.J., Brehm, A. & Kouzarides, T. Regulation of E2F1 activity by acetylation. EMBO J. 19, 662–671 (2000).
Ogryzko, V.V., Schiltz, R.L., Russanova, V., Howard, B.H. & Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953–959 (1996).
Boyes, J., Byfield, P., Nakatani, Y. & Ogryzko, V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396, 594–598 (1998).
Chan, H.M. & La Thangue, N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114, 2363–2373 (2001).
Zhang, W., Bone, J.R., Edmondson, D.G., Turner, B.M. & Roth, S.Y. Essential and redundant functions of histone acetylation revealed by mutation of target lysines and loss of the Gcn5p acetyltransferase. EMBO J. 17, 3155–3167 (1998).
Ng, H.H. & Bird, A. Histone deacetylases: silencers for hire. Trends Biochem. Sci. 25, 121–126 (2000).
Albagli, O. et al. Multiple domains participate in distance-independent LAZ3/BCL6-mediated transcriptional repression. Biochem. Biophys. Res. Commun. 220, 911–915 (1996).
Huynh, K.D. & Bardwell, V.J. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 17, 2473–2484 (1998).
Marks, P.A., Richon, V.M. & Rifkind, R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92, 1210–1216 (2000).
Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149–159 (2001).
Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107, 137–148 (2001).
Iida, S. et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genet. 17, 226–230 (1997).
Sakaguchi, K. et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831–2841 (1998).
Zhang, H., Okada, S., Hatano, M., Okabe, S. & Tokuhisa, T. A new functional domain of Bcl6 family that recruits histone deacetylases. Biochim. Biophys. Acta 1540, 188–200 (2001).
Cress, W.D. & Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 184, 1–16 (2000).
Imai, S., Armstrong, C.M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795–800 (2000).
Guarente, L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14, 1021–1026 (2000).
Luo, J., Su, F., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408, 377–381 (2000).
Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W. & Vogelstein, B. A model for p53-induced apoptosis. Nature 389, 300–305 (1997).
Gaidano, G. et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 88, 5413–5417 (1991).
Moller, M.B., Gerdes, A.M., Skjodt, K., Mortensen, L.S. & Pedersen, N.T. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 1085–1091 (1999).
Acknowledgements
We thank R. Baer and L. Pasqualucci for critical reading of the manuscript; U. Klein and G. Cattoretti for the isolation of human B cells; and J.C. Luo for the preliminary experiments on in vivo and in vitro interaction of p300 and BCL6. This work was supported by the US National Institutes of Health (to R.D.-F.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bereshchenko, O., Gu, W. & Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32, 606–613 (2002). https://doi.org/10.1038/ng1018
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng1018
This article is cited by
-
SIRT1 and HSP90α feed-forward circuit safeguards chromosome segregation integrity in diffuse large B cell lymphomas
Cell Death & Disease (2023)
-
The regulation of Tfh cell differentiation by β-hydroxybutyrylation modification of transcription factor Bcl6
Chromosoma (2023)
-
Altered pathways and targeted therapy in double hit lymphoma
Journal of Hematology & Oncology (2022)
-
Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition
Oncogene (2022)
-
Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies
Signal Transduction and Targeted Therapy (2021)